Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: ASKA Pharmaceutical Holdings Co.,Ltd.

Market Cap 65.51B 409M 353M 324M 305M 574M 38.58B 578M 3.84B 1.5B 18.94B 1.53B 1.5B P/E 2026
12.3x
P/E 2027 * 11.7x
Enterprise Value 65.51B 409M 353M 324M 305M 574M 38.58B 578M 3.84B 1.5B 18.94B 1.53B 1.5B EV / Sales 2026
0.94x
EV / Sales 2027 * 0.92x
Free-Float
61.83%
Yield 2026
2.54%
Yield 2027 * 2.25%
05-27 Dalton Investment strongly oppose conditional activation of countermeasures announced by ASKA Pharmaceutical Holdings on May 25 RE
05-25 Aska pharmaceutical - plan to put to shareholders proposal on countermeasures against potential large-scale share purchase by Dalton and related parties RE
05-11 Asuka Pharmaceutical Opposes Nippon Active Value Fund Plc?s Shareholder Proposal for Board Changes at 2026 Annual Meeting CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Change in Dividend Policy CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Proposes Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 25, 2026; Provides Dividend Guidance for End of Second Quarter of Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Retirement of Kazuhiro Chiku as Audit & Supervisory Board Member, Effective June 24, 2026 CI
04-13 FTS AMBROSE HOLDINGS, INC. announced that it has received funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
03-24 Insilico Medicine And ASKA Pharmaceutical Enter Strategic Research Collaboration For Women's Health CI
03-23 Aska Pharmaceutical Holdings Co Ltd - Insilico Medicine and Aska Pharmaceutical expand partnership to discover novel targets for women's health RE
03-23 ASKA Targets 85 Billion Yen Revenue Under New Mid-term Plan MT
02-02 ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
1 day-2.33%
1 week-9.17%
Current month-21.26%
1 month-17.84%
3 months+4.53%
6 months+16.10%
Current year+13.20%
1 week 2,292
Extreme 2292
2,453
1 month 2,292
Extreme 2292
3,045
Current year 2,038
Extreme 2038
3,045
1 year 1,920
Extreme 1920
3,045
3 years 1,353
Extreme 1353
3,045
5 years 919
Extreme 919
3,045
10 years 776
Extreme 776
3,045
Manager TitleAgeSince
Chief Executive Officer - -
President 42 2025-06-23
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 74 2025-06-23
Director/Board Member 67 2021-03-31
Director/Board Member 42 2021-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-9.17%-0.99%+71.78% 418M
-0.94%-2.14%+40.54%+146.04% 1,001B
-0.42%-1.80%+53.69%+42.69% 566B
-0.56%-1.65%+19.27%+60.52% 393B
+3.82%+2.29%+24.04%+16.53% 326B
+1.09%+2.21%+25.56%+33.32% 276B
+1.42%-1.17%+24.53%+14.29% 277B
+1.87%+5.96%-42.67%-48.26% 193B
-1.78%+1.16%+17.79%+49.46% 188B
-1.40%+3.27%+16.16%+61.43% 158B
Average -0.50%-0.38%+17.79%+44.78% 337.72B
Weighted average by Cap. -0.35%-0.41%+28.99%+65.85%

Financials

2026 2027 *
Net sales 69.09B 431M 372M 342M 322M 605M 40.69B 610M 4.05B 1.58B 19.97B 1.62B 1.58B 71.06B 444M 383M 352M 331M 622M 41.86B 627M 4.17B 1.62B 20.54B 1.66B 1.63B
Net income 5.19B 32.37M 27.93M 25.68M 24.17M 45.41M 3.06B 45.79M 304M 118M 1.5B 121M 119M 5.6B 34.97M 30.17M 27.74M 26.11M 49.05M 3.3B 49.47M 329M 128M 1.62B 131M 128M
Net Debt - -
Logo ASKA Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company primarily engaged in the pharmaceutical business. The Company has three business segments. The Pharmaceutical Business segment primarily manufactures and sells prescription pharmaceuticals. The Animal Health Business segment primarily manufactures and sells veterinary medicines, feed additives, and other products. The Overseas Business segment primarily manufactures and sells prescription pharmaceuticals overseas. The Company also engages in clinical testing and medical equipment businesses.
Employees
1,632
Date Price Change Volume
26-06-17 2,307.00 ¥ -2.33% 124,800
26-06-16 2,362.00 ¥ 0.00% 81,700
26-06-15 2,362.00 ¥ -2.28% 97,200
26-06-12 2,417.00 ¥ +0.21% 80,400
26-06-11 2,412.00 ¥ -1.35% 80,500
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2,307.00JPY
Average target price
2,500.00JPY
Spread / Average Target
+8.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4886 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!